Ace inhibitor

The European Commission ( EC ) has approved Rinvoq ( Upadacitinib, 15 mg ), an oral, once daily selective and...


The co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance were presented. The primary objective of...


New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell...


The results from the final analysis of the phase 3 TITAN study, which has demonstrated the continued statistically significant benefit...


The FDA ( US Food and Drug Administration ) has approved the following expanded indication for Entresto ( Sacubitril /...


The European Commission ( EC ) has granted marketing authorization for Tukysa ( Tucatinib ) in combination with Trastuzumab and...


The FDA ( U.S. Food and Drug Administration ) has approved Sarclisa ( Isatuximab ) in combination with Carfilzomib and...


Farxiga ( Dapagliflozin ), a sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor, has been approved in the US to reduce...


Results from two pivotal phase 3 trials evaluating Deucravacitinib, an oral, selective tyrosine kinase 2 ( TYK2 ) inhibitor, for...


The European Commission ( EC ) has approved Sarclisa ( Isatuximab ) in combination with Carfilzomib and Dexamethasone ( Kd...


Klisyri ( Tirbanibulin ) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis ( AK )...


Tagrisso ( Osimertinib ), an irreversible epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ), has been approved...


Dalpiciclib, a novel CDK4/6 inhibitor, as monotherapy has demonstrated tolerability and preliminary antitumor activity in pretreated HR+/HER2− advanced breast cancer...


The U.S. Food and Drug Administration ( FDA ) has approved the combination of Keytruda ( Pembrolizumab ), an anti-PD-1...


Hyperkalaemia is a common complication of type 2 diabetes mellitus ( T2DM ) and limits the optimal use of agents...


The European Commission ( EC ) has approved the extension of the indication of Invokana ( Canagliflozin ) to include...


The European Commission ( EC ) has approved Rinvoq ( Upadacitinib ), an oral, selective and reversible JAK inhibitor, for...


An update of the European League Against Rheumatism ( EULAR ) rheumatoid arthritis management recommendations to account for the most...


The European Commission ( EC ) has granted marketing authorization for Jyseleca ( Filgotinib 200 mg and 100 mg tablets...